Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Bio­gen CEO Michel Vounatsos on Thurs­day ad­mit­ted the com­pa­ny is ex­pe­ri­enc­ing some “near term chal­lenges” in launch­ing its con­tro­ver­sial new Alzheimer’s drug, a lit­tle more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER